百濟神州(06160.HK)與Royalty Pharma Investments2023 ICAV簽訂一份特許權使用費購買協議
格隆匯8月25日丨百濟神州(06160.HK)公告,於2025年8月25日,公司、公司的子公司BeOne Medicines I GmbH(賣方)與Royalty Pharma Investments2023 ICAV(獨立第三方)簽訂了一份特許權使用費購買協議。
根據特許權使用費購買協議,Royalty Pharma同意在交割時向賣方支付8.85億美元首付款,向賣方購買其就任何及所有包含單克隆抗體Imdelltra (tarlatamab)(包括任何劑量、形式(包括聚乙二醇化版本)、製劑(無論短效還是長效)、給藥方式或給藥途徑產品(合稱Imdelltra產品)在中國以外地區年度銷售的淨收入(Imdelltra中國外淨收入)收取分級計算的中個位數百分比的特許權使用費的大部分權利。前述特許權使用費系Amgen Inc.根據公司、賣方和安進於2019年10月31日簽訂並不時修訂的合作協議向賣方支付的費用。此外,自交割至2026年8月25日,賣方有權自行決定向Royalty Pharma出售額外的收取特許權使用費的權利,行使賣出選擇權可使賣方獲得最高達6,500萬美元的額外付款,該付款將根據額外的特許權使用費的價值按比例進行調整。對於年度Imdelltra中國外淨收入超過15億美元的部分,賣方將分享特許權使用費的一部分。除保留以上描述的收取特許權使用費的權利外,賣方還保留了安進合作協議項下的其他經濟利益。
公司已評估特許權使用費購買協議,並預期根據美國公認會計原則,RoyaltyPharma支付的首付款將於交割時構成公司的一項重大直接財務義務。基於該會計處理,特許權使用費購買協議項下擬進行的交易不構成上市規則項下公司任何須予公佈交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.